KOSDAQMedia & Entertainment0010S0

와이즈플래닛컴퍼니

₩17,750▼ 6.68%2026-10-02 close

Market Cap

₩179.7B

Turnover

₩12.5B

Volume

670,000 shares

Shares out.

10M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Margins Improving, Revenue Re-Acceleration Still Unproven

A Dr.Piel-anchored D2C brand commerce company that debuted on KOSDAQ in September 2026, with H1 2026 margin improvement as a clear bright spot, while top-line concentration and stalled revenue growth remain the central variables.

1
KOSDAQ debut on Sept 23, 2026 with a ~286% first-day surge above the KRW 12,000 IPO price; as of Oct 3, the stock trades at KRW 17,750, approximately 48% above IPO price
2
H1 2026 operating margin surged to 9.2% from 4.2% a year ago, with revenue of KRW 33.2bn (+6.8% YoY) and operating profit of KRW 3.0bn (+131.2% YoY), driven by Dr.Piel repeat purchases and cost efficiency
3
Dr.Piel accounted for 67.9% of Q1 2026 total revenue; elevated single-brand concentration makes portfolio diversification the key long-term stability variable
4
Consolidated revenue was range-bound at KRW 64.1–69.4bn over 2023–2025; the 2025 decline was attributed to the deliberate wind-down of low-margin live shopping channels
5
Of IPO proceeds of up to KRW 19.2bn, KRW 4.5bn is allocated for offline experience centers and overseas D2C sites (2026–2028) and KRW 5.7bn for global marketing and talent, targeting Japan and Amazon channels

Business structure

WisePlanet Company operates across two primary business pillars. The first is a performance digital marketing agency providing services to external clients; the second is a proprietary media commerce arm that directly plans, markets, and sells self-owned consumer brands.

The media commerce segment comprises Dr.Piel (living healthcare/bathroom fixtures), Nujam (bedding), Irenol (cosmetics), Citify (small appliances), and Chaesikjuui (vegan skincare); as of Q1 2026, Dr.Piel alone represented approximately 67.9% of total revenue, highlighting significant single-brand concentration.

Dr.Piel centers on filter-replacement shower heads and hoses, generating inherent recurring consumable demand—the brand reportedly achieved a repurchase rate of 55%.

All products are manufactured externally via OEM/ODM arrangements, with WisePlanet handling only brand planning, marketing, and distribution in an asset-light model.

The proprietary integrated data platform 'WAPL' is the operational backbone, consolidating sales, inventory, logistics, and CRM while recycling D2C first-party consumer data back into marketing decisions, creating a self-reinforcing feedback loop.

The core business model differentiator is the application of performance marketing expertise accumulated through the agency business to accelerate proprietary brand growth.

On the investment front, minority strategic stakes in dalba (cosmetics), Bark (shoes), Dansaek (femtech), and Wefun (corporate welfare platform) provide medium-to-long-term portfolio expansion optionality.

In the competitive landscape, WisePlanet competes with D2C media commerce peers such as Eco Marketing, Blank Corporation, and dalba global, with a category-leadership-per-brand strategy as its primary differentiator.

Recent trends

On a consolidated basis, FY2025 annual revenue was KRW 64.8bn, down 6.5% from KRW 69.4bn in FY2024; however, operating profit held firm at KRW 6.3bn, roughly in line with the prior year.

The revenue decline was deliberate—stemming from the wind-down of low-margin live shopping channels—while the operating margin edged up from approximately 9.0% in FY2024 to 9.8% in FY2025.

Consolidated revenue oscillated within a KRW 64.1–69.4bn range over three consecutive years (2023–2025), while operating profit moved incrementally from KRW 6.0bn to KRW 6.3bn.

In H1 2026, the pace of profitability improvement accelerated markedly: revenue grew 6.8% year-over-year to KRW 33.2bn, operating profit surged 131.2% to KRW 3.0bn, and net income jumped 155.2% to KRW 3.7bn, with the operating margin nearly doubling from 4.2% to 9.2%.

At the brand level, Dr.Piel's H1 2026 revenue reached KRW 21.0bn (+39% YoY) with a contribution margin of 21.6%, as growing repeat purchases of filter-replacement products drove marketing efficiency gains.

Nujam maintained revenue of KRW 8.8bn while its contribution margin expanded sharply from 8.1% to 17.4%, demonstrating that profitability improvements are broadening across multiple brands.

Irenol more than doubled from KRW 3.0bn in 2024 to KRW 6.4bn in 2025 and is emerging as a next-generation growth driver, with the combined revenue share of Irenol, Citify, and Chaesikjuui rising from 9.2% in 2023 to 13.4% in 2025.

On the stock front, WisePlanet surged approximately 285–286% above its KRW 12,000 IPO price on its September 23 debut, closing at KRW 45,700–46,300; profit-taking then intensified, pushing the price to KRW 38,200 on September 28 and further to KRW 17,750 by October 3, placing the stock at roughly 48% above its IPO price after approximately ten trading sessions.

Outlook

In the near term, the release of institutional investor lock-up commitments and increases in freely tradable shares are expected to be a key driver of share price volatility.

The medium-term growth strategy centers on a dual-track approach: expanding the revenue contribution of newer brands such as Irenol and Citify to reduce Dr.Piel concentration, while maintaining the flagship's growth trajectory via new product lines.

Kiwoom Securities, cited in reporting at the time of listing, noted that while the company's profit stability is commendable, the deceleration in revenue growth relative to peers such as dalba global and Aromatica warrants attention, with a pattern of growth stalling once individual brands reach a certain sales level.

On global expansion, Irenol's placement in approximately 300 offline stores in Japan has already been confirmed, and KRW 4.5bn of IPO proceeds is earmarked for domestic experience centers and overseas D2C site development through 2028.

The strategic investment portfolio (dalba, Dansaek, etc.) represents optionality for medium-to-long-term growth, though near-term earnings contribution from these holdings remains limited.

With rising customer acquisition costs (CAC) a structural headwind across the D2C sector globally, Dr.Piel's filter-replacement recurring purchase model offers a relative CRM efficiency advantage.

The pending FSS review of FY2025 financial statements remains an outstanding disclosure-related uncertainty, and its resolution will likely be a benchmark for market confidence in the reported financial record.

Bull factors

Recurring-Purchase Model Underpinning Margin Expansion

Dr.Piel's filter-replacement shower products generate inherent refill demand after initial purchase, with the brand reportedly achieving a repurchase rate of 55%; this growing repeat-purchase base has improved marketing return relative to customer acquisition costs.

Dr.Piel's H1 2026 contribution margin reached 21.6%, while Nujam's contribution margin more than doubled from 8.1% to 17.4% over the same period, signaling that profitability improvement is broadening across multiple brands.

The overall operating margin reached 9.2% in H1 2026, up sharply from 4.2% a year earlier, driven by a combination of cost efficiency and the increasing share of high-retention repeat purchases in the revenue mix.

With operating profit growing consistently over three years and the pace of H1 2026 earnings growth accelerating markedly, the structural profit improvement has become more visible.

Zero Net Debt and Strong Capital Efficiency

The consolidated debt-to-equity ratio of just 14.7% in FY2025, coupled with negligible borrowing dependence, distinguishes WisePlanet's financial health within the D2C and media commerce sector.

IPO proceeds are earmarked entirely for growth investments, and the management's articulated 'Snowball' strategy of compounding retained earnings without excessive external financing supports sustainable balance sheet strength.

An FY2025 consolidated ROE of 22.7% reflects sound capital efficiency, while a high equity ratio of 86.9% provides flexibility for future investment needs. The KOSDAQ listing also raises market visibility and governance credibility, potentially expanding access to strategic partnerships and capital markets.

Irenol Growth and Global Expansion as Portfolio Options

Irenol's annual revenue more than doubled from KRW 3.0bn in 2024 to KRW 6.4bn in 2025, positioning it as the next growth engine behind Dr.Piel.

Irenol has ranked No.1 in the cream concealer category on Qoo10 Japan and secured placement in approximately 300 offline stores in Japan, providing early-stage validation of international demand.

The combined revenue share of Irenol, Citify, and Chaesikjuui expanded from 9.2% in 2023 to 13.4% in 2025, making portfolio diversification tangible rather than aspirational.

IPO proceeds allocated toward global e-commerce channels such as Amazon, along with strategic stakes in dalba and Dansaek, represent additional optionality for medium-to-long-term growth.

Bear factors

High Revenue Concentration in Dr.Piel

Dr.Piel accounted for 67.9% of Q1 2026 total revenue, meaning any deterioration in that brand's trajectory directly impacts overall company results. Dr.Piel's annual revenue growth was in the low single digits from 2023 to 2025 (KRW 32.3bn → 34.0bn → 36.0bn), raising questions about potential saturation.

Kiwoom Securities noted at the time of listing that a pattern of growth stalling once brands reach a certain revenue threshold has been observed repeatedly across the company's portfolio.

This reliance on a single category leader creates structural vulnerability to intensifying competition, evolving consumer preferences, and shifts in platform algorithm and exposure policies.

Three-Year Revenue Plateau and Uncertain Re-Acceleration

Consolidated revenue was effectively range-bound between KRW 64.1bn and KRW 69.4bn over 2023–2025, with no meaningful top-line expansion across the three-year period.

While the 2025 revenue decline was a strategic choice to exit low-margin live shopping channels, it remains unverified whether newer brands can sufficiently offset the growth deceleration at the flagship Dr.Piel line.

H1 2026 revenue growth of just 6.8% year-over-year makes it difficult to confirm a definitive top-line re-acceleration on an annualized basis.

If investment in new brands and global market entry requires a step-up in marketing spending, the current margin improvement trajectory may prove difficult to sustain concurrently.

Post-IPO Price Volatility and Supply Overhang

Although the initial public float was limited to just 21.12% (approximately 2.11 million shares), the stock surged approximately 286% on its listing day and has since corrected by more than 60% from the first-day intraday peak (around KRW 46,000), trading at KRW 17,750 as of October 3.

CEO Joo Kyung-min's 61.39% stake (post-IPO) is subject to a 30-month lock-up, but near-term expiry of shorter lock-ups for institutional investors and employee shareholders could create incremental supply pressure.

The FSS review of FY2025 financial statements was ongoing at the time of listing and remains unresolved, representing a disclosure-related uncertainty that could affect reported financial figures and investor confidence.

As a newly listed company, earnings track record verification requires time, and upcoming quarterly disclosures are expected to function as pivotal market-sentiment events.

Risk factors

Regulatory & Disclosure Risk

The Financial Supervisory Service (FSS) commenced a review of WisePlanet Company's FY2025 financial statements on April 29, 2026, and the review had not been concluded by the time the securities registration statement was filed or the company listed.

Should the FSS review result in restatements or impose additional disclosure obligations, investor confidence and market valuation could be affected.

Historical Korean IPO cases have shown instances where prolonged accounting reviews led to listing delays or withdrawals, sustaining uncertainty until the result is published.

As a newly minted KOSDAQ company, the firm now faces ongoing quarterly reporting and fair-disclosure obligations that add operational compliance burden.

Industry & Competitive Risk

The D2C and media commerce sector faces a structural headwind from rising customer acquisition costs (CAC) as performance marketing competition intensifies; global digital advertising prices are estimated to have risen more than 30% since 2022.

Higher reliance on domestic open-market platforms exposes brands to growing commission burdens and algorithm-dependent traffic risks, making the pace of D2C own-channel migration a critical swing factor.

Competitors such as Eco Marketing and dalba global are aggressively pursuing similar strategies—reinforcing D2C channels, expanding internationally, and diversifying product lines—making the defense of category-leading positions increasingly difficult.

The growing presence of low-cost Chinese consumer goods through Korean e-commerce platforms ('C-commerce') represents an additional risk that could further intensify price competition in the living goods and beauty segments.

Macro & FX Risk

A slowdown in domestic private consumption could dampen demand for the company's core product categories, including living goods, bedding, and cosmetics.

As Japan and the United States are primary targets for global expansion, exchange rate volatility—particularly in the KRW/JPY and KRW/USD pairs—could directly impact the profitability of overseas operations and introduce earnings uncertainty.

Under the OEM/ODM outsourcing model, raw material price increases or supply chain disruptions may compress margins if cost increases cannot be passed through to end consumers.

Despite the continued growth of the overall e-commerce market, the structural concentration of value capture within dominant platforms could constrain profitability for D2C brand companies more broadly.

Overall view

WisePlanet Company is a media commerce brand builder that reportedly achieved a CAGR of 53.1% from 2014 onward, backed by a solid financial foundation of three consecutive years of profitability, a low debt-to-equity ratio of 14.7%, and an ROE of 22.7%.

The H1 2026 operating margin improvement to 9.2% signals that the combined effect of growing repeat purchases and cost efficiency is gaining meaningful traction.

Nevertheless, consolidated revenue has been range-bound at KRW 64.1–69.4bn for three years, and Dr.Piel's concentration at approximately 67.9% of quarterly revenue remains elevated, making revenue re-acceleration and brand portfolio diversification the pivotal medium-to-long-term fundamental variables.

Supply-side volatility in the wake of the post-IPO price surge and correction, the pending FSS financial statement review, and the early-stage nature of global expansion collectively represent a compound of near-term uncertainties.

In the near term, upcoming quarterly earnings disclosures and the schedule of institutional lock-up expiries are likely to function as key market observation points.

In summary, the company demonstrates sound profitability and balance sheet fundamentals, but the pace of progress on three distinct challenges—revenue re-acceleration, reduction of Dr.Piel concentration, and measurable global traction—will be the central determinants of any substantive fundamental reappraisal.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 11 more articles and sources

Report written 2026-10-03 · Data as of 2026-10-02

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.